Clinical trial
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary…
NCT00402272 · Abbott Medical Devices, Industry · Completed
Key facts
| NCT number | NCT00402272 |
|---|---|
| Title | SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe |
| Official title | SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions |
| Acronym | SPIRIT V |
| Lead sponsor | Abbott Medical Devices, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Disease, Coronary Artery Disease, Coronary Restenosis |
| Intervention type | Device |
| Interventions | XIENCE V® Everolimus Eluting Coronary Stent |
| Enrollment | 2,700 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Nov 22, 2006 |
| Last update posted | Oct 14, 2010 |
| Countries | Austria, Belgium, Canada, China, Czechia, France, Germany, Greece, India, Ireland, Israel, Italy and 11 more |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: